Cargando…

Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome

BACKGROUND: Serum baseline tryptase (sBT) is a minor diagnostic criterion for systemic mastocytosis (SM) of undetermined prognostic impact. We monitored sBT levels in indolent SM (ISM) patients and investigated its utility for predicting disease behaviour and outcome. METHODS: In total 74 adult ISM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matito, Almudena, Morgado, José Mario, Álvarez-Twose, Iván, Laura Sánchez-Muñoz, Pedreira, Carlos Eduardo, Jara-Acevedo, María, Teodosio, Cristina, Sánchez-López, Paula, Fernández-Núñez, Elisa, Moreno-Borque, Ricardo, García-Montero, Andrés, Orfao, Alberto, Escribano, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796517/ https://www.ncbi.nlm.nih.gov/pubmed/24155887 http://dx.doi.org/10.1371/journal.pone.0076116

Ejemplares similares

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis
por: Dasilva-Freire, Noelia, et al.
Publicado: (2019)

Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
por: Rama, Tiago Azenha, et al.
Publicado: (2022)

Altered innate immune profile in blood of systemic mastocytosis patients
por: Pérez‐Pons, Alba, et al.
Publicado: (2022)

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes
por: González-de-Olano, David, et al.
Publicado: (2016)

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
por: Selcuk, Ali, et al.
Publicado: (2021)

Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis
por: González-López, Oscar, et al.
Publicado: (2022)

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2020)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

The role of serum tryptase in the diagnosis and monitoring of pediatric mastocytosis: a single-center experience
por: Lange, Magdalena, et al.
Publicado: (2017)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

Indolent systemic mastocytosis in a patient with ileocolitis
por: Chrysakopoulos, Georgios, et al.
Publicado: (2014)

Delayed Diagnosis of Adult Indolent Systemic Mastocytosis
por: Mikkelsen, Carsten Sauer, et al.
Publicado: (2014)

Indolent systemic mastocytosis mimicking Crohn’s disease
por: Hadjivasilis, Alexandros, et al.
Publicado: (2019)

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock
por: Chatterjee, Manidipam, et al.
Publicado: (2018)

Primary cicatricial alopecia associated with systemic indolent mastocytosis
por: Prasad, Sonya, et al.
Publicado: (2020)

DNA methylation profile in patients with indolent systemic mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2021)

Indolent systemic mastocytosis associated with light chain deposition disease
por: Sasaki, Kotaro, et al.
Publicado: (2012)

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis”
por: Moshref Razavi, Habib, et al.
Publicado: (2022)

Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas
por: González-Tablas, María, et al.
Publicado: (2021)

Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome
por: Conde-Fernandes, Iolanda, et al.
Publicado: (2017)

PD34 - Childhood mastocytosis: serum baseline total tryptase levels and extent of cutaneous disease as predictors of mast cell mediator release symptoms
por: Chatzipetrou, Alexia, et al.
Publicado: (2014)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Intertriginous maculopapular mastocytosis in a patient with acute myeloid leukemia
por: Herrero-Moyano, María, et al.
Publicado: (2017)

Pancreatic neuroendocrine tumor presenting in indolent systemic mastocytosis: A case report
por: Sacco, Keith, et al.
Publicado: (2020)

Genome-Wide DNA Methylation and Gene Expression in Patients with Indolent Systemic Mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2023)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(−) mesenchymal stem cells in human bone marrow
por: Muñiz, Carmen, et al.
Publicado: (2015)

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report
por: Alshurafa, Awni, et al.
Publicado: (2023)

Mast cell tryptase and asthma
por: Zhang, M-Q., et al.
Publicado: (1997)

Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021
por: Lange, Magdalena, et al.
Publicado: (2021)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches
por: Paiva, Marcelo L., et al.
Publicado: (2023)

Circulating Tryptase as a Marker for Subclinical Atherosclerosis in Obese Subjects
por: Moreno, María, et al.
Publicado: (2014)

New Biomarkers in Anaphylaxis (Beyond Tryptase)
por: Galvan-Blasco, P., et al.
Publicado: (2022)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0ibet1rfu2nqomcnng1e133bn